NCCN VERSION 2 2015

158 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-83
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
225. Romond E, Suman V, Jeong J-H, et al. Trastuzumab plus adjuvant
chemotherapy for HER2-positive breast cancer: Final planned joint
analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831.
Cancer Research 2012;72:S5-5. Available at:
eetingAbstracts/S5-5.
226. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in
HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
Available at: .
227. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the
efficacy and safety of humanized anti-HER2 monoclonal antibody in
women who have HER2-overexpressing metastatic breast cancer that
has progressed after chemotherapy for metastatic disease. J Clin Oncol
1999;17:2639-2648. Available at:
.
228. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic breast cancer
that overexpresses HER2. N Engl J Med 2001;344:783-792. Available
at:
229. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of
trastuzumab as a single agent in first-line treatment of HER2-
overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-
726. Available at: .
230. Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis
and therapeutic prediction in breast cancer. J Natl Compr Canc Netw
2005;3:291-300. Available at:
.
231. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene
expression patterns in human mammary epithelial cells and breast
cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217. Available at:
.
232. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns
of breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci U S A 2001;98:10869-10874. Available
at:
233. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of
breast tumor subtypes in independent gene expression data sets. Proc
Natl Acad Sci U S A 2003;100:8418-8423. Available at:
.
234. Paik S, Shak S, Tang G, et al. A multigene assay to predict
recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J
Med 2004;351:2817-2826. Available at:
.
235. Paik S, Tang G, Shak S, et al. Gene expression and benefit of
chemotherapy in women with node-negative, estrogen receptor-positive
breast cancer. J Clin Oncol 2006;24:3726-3734. Available at:
.
236. Fan C, Oh DS, Wessels L, et al. Concordance among gene-
expression-based predictors for breast cancer. N Engl J Med
2006;355:560-569. Available at:
.
237. Wang Y, Klijn JGM, Zhang Y, et al. Gene-expression profiles to
predict distant metastasis of lymph-node-negative primary breast
cancer. Lancet 2005;365:671-679. Available at:
.
238. Glas AM, Floore A, Delahaye LJMJ, et al. Converting a breast
cancer microarray signature into a high-throughput diagnostic test. BMC
Genomics 2006;7:278-278. Available at:
.
239. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression
signature as a predictor of survival in breast cancer. N Engl J Med